Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major ...

Investors will likely focus on the sales performance of AbbVie's blockbuster immunology drugs, Rinvoq and Skyrizi, when it ...

Not only are pharmaceutical stocks excellent defensive investments, some pharma stocks pay sizable dividends that can be a ...

AbbVie generated $56 billion in revenue, achieving an operating profit of $12 billion and a net income of $4.3 billion, ...

Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya ...

Galapagos (Euronext: GLPG) has appointed Henry Gosebruch as chief executive of its upcoming oncology spin-off, marking a ...

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

But AbbVie planned exceptionally well for this loss of exclusivity. Its two successors to Humira (Rinvoq and Skyrizi) are on track to generate more sales combined than Humira did at its peak. AbbVie ...

BofA lowered the firm’s price target on AbbVie (ABBV) to $200 from $223 and keeps a Neutral rating on the shares. The firm updated estimates ...

Merck MRK and AbbVie ABBV are leading pharmaceutical companies with strong portfolios in oncology and immunology. While ...